A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP …
F Griesinger, W Eberhardt, A Nusch, M Reiser… - Lung Cancer, 2021 - Elsevier
Objectives An increasing number of treatment-determining biomarkers has been identified in
non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable …
non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable …
[HTML][HTML] Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
NJ Robert, JL Espirito, L Chen, E Nwokeji, M Karhade… - Lung Cancer, 2022 - Elsevier
Abstract Objectives The MYLUNG (Molecularly Informed Lung Cancer Treatment in a
Community Cancer Network) consortium pragmatic study assessed real-world biomarker …
Community Cancer Network) consortium pragmatic study assessed real-world biomarker …
[HTML][HTML] KRAS G12C–mutant non–small cell lung cancer: biology, developmental therapeutics, and molecular testing
R Veluswamy, PC Mack, J Houldsworth… - The Journal of Molecular …, 2021 - Elsevier
Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …
[HTML][HTML] Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
JP Gregg, T Li, KY Yoneda - Translational lung cancer research, 2019 - ncbi.nlm.nih.gov
Molecular testing identifies patients with advanced non-small cell lung cancer (NSCLC) who
may benefit from targeted therapy or immunotherapy (ie, immune checkpoint inhibitor …
may benefit from targeted therapy or immunotherapy (ie, immune checkpoint inhibitor …
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with …
J Vanderpoel, AL Stevens, B Emond… - Journal of Medical …, 2022 - Taylor & Francis
Background To assess the total cost of testing associated with next-generation sequencing
(NGS) versus polymerase chain reaction (PCR) testing strategies among patients with …
(NGS) versus polymerase chain reaction (PCR) testing strategies among patients with …
Development and clinical application of radiomics in lung cancer
B Chen, R Zhang, Y Gan, L Yang, W Li - Radiation oncology, 2017 - Springer
Since the discovery of X-rays at the end of the 19 th century, medical imageology has
progressed for 100 years, and medical imaging has become an important auxiliary tool for …
progressed for 100 years, and medical imaging has become an important auxiliary tool for …
The evolutional history of electromagnetic navigation bronchoscopy: state of the art
AC Mehta, KL Hood, Y Schwarz, SB Solomon - Chest, 2018 - Elsevier
Electromagnetic navigation bronchoscopy (ENB) has come a long way from the early roots
of electromagnetic theory. Current ENB devices have the potential to change the way lung …
of electromagnetic theory. Current ENB devices have the potential to change the way lung …
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: results of a survey of US oncologists
KF Mileham, C Schenkel, SS Bruinooge… - Cancer …, 2022 - Wiley Online Library
Background An ASCO taskforce comprised of representatives of oncology clinicians, the
American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 …
American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 …
Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non–small-cell lung cancer
R Palmero, A Taus, S Viteri, M Majem… - JCO Precision …, 2021 - ascopubs.org
Purpose Treatment guidelines for advanced non–small-cell lung cancer (aNSCLC)
recommend broad molecular profiling for targeted therapy selection. This study …
recommend broad molecular profiling for targeted therapy selection. This study …